https://www.healthworldmauritania.com/article/908452226-addgene-reinforces-its-expanding-role-in-research-with-new-brand Health World Mauritania en PressRelease 2026-04-27T13:30:00+00:00 Addgene Reinforces Its Expanding Role in Research with New Brand https://ml.globenewswire.com/media/e4b4a6b0-9eac-49c5-852f-53fce9ecf258/small/addgene-logo-blue-png.png https://www.healthworldmauritania.com/article/908452255-siren-biotechnology-publishes-foundational-aav-immuno-gene-therapy-data-and-announces-presentations-at-asgct-2026 Health World Mauritania en PressRelease 2026-04-27T13:30:00+00:00 Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026 https://ml.globenewswire.com/media/85723172-4ddc-4c45-bfcc-98d753f7563c/small/siren-bio-logo-with-name-png.png https://www.healthworldmauritania.com/article/908452311-polyrizon-announces-filing-of-european-patent-application-for-its-breakthrough-drug-delivery-platform Health World Mauritania en PressRelease 2026-04-27T13:28:00+00:00 Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform https://ml.globenewswire.com/media/YmQ4YTU5MTctMWM0Mi00ZWRiLTg5MWYtM2JiYzU0ZWQwNGU3LTUwMDEyOTIyMy0yMDI2LTA0LTI3LWVu/tiny/Polyrizon-Ltd-.png https://www.healthworldmauritania.com/article/908452389-wellspan-behavioral-health-walk-in-crisis-center-opens-in-york Health World Mauritania en PressRelease 2026-04-27T13:21:56+00:00 WellSpan Behavioral Health Walk-In Crisis Center opens in York https://ml.globenewswire.com/media/YmZiYTY1MTktMjk0Ny00NDYxLTk1N2ItYWQyODFmMGM2YjdhLTEyMjE1MzQtMjAyNi0wNC0yNy1lbg==/tiny/WellSpan-Health.png https://www.healthworldmauritania.com/article/908448054-sharecare-surpasses-1-million-hours-of-home-care-delivered-to-veterans-through-u-s-department-of-veterans-affairs-community-care-network Health World Mauritania en PressRelease 2026-04-27T13:03:56+00:00 Sharecare surpasses 1 million hours of home care delivered to Veterans through U.S. Department of Veterans Affairs Community Care Network https://ml.globenewswire.com/media/ab8cd27b-be52-406c-96ee-1a905002590b/small/new-logo-jpeg.jpeg https://www.healthworldmauritania.com/article/908447950-alpha-tau-announces-presentation-of-pancreatic-cancer-data-at-upcoming-asco-annual-meeting-showcasing-combined-results-from-three-alpha-dart Health World Mauritania en PressRelease 2026-04-27T13:01:00+00:00 Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.healthworldmauritania.com/article/908447580-exagen-inc-to-announce-first-quarter-financial-results-on-may-11-2026 Health World Mauritania en PressRelease 2026-04-27T13:00:00+00:00 Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026 https://ml.globenewswire.com/media/56891beb-9424-4bd8-98ed-ade5f6c1f4c6/small/exagen-logo-288-x-103-px-tranparent-background-png.png https://www.healthworldmauritania.com/article/908447604-ms-canada-calls-on-canadians-to-take-action-during-ms-awareness-month-towards-a-world-free-of-ms Health World Mauritania en PressRelease 2026-04-27T13:00:00+00:00 MS Canada Calls on Canadians to Take Action During MS Awareness Month Towards a World Free of MS https://ml.globenewswire.com/media/NDFlNTI0NGItOGQzMy00NDYxLWEyY2ItNzZjY2U1YTcyYjE1LTUwMDEyNTMxMy0yMDI2LTA0LTI3LWVu/tiny/MS-Canada.png https://www.healthworldmauritania.com/article/908447928-nexgel-appoints-ian-blackman-as-chief-financial-officer Health World Mauritania en PressRelease 2026-04-27T13:00:00+00:00 NEXGEL Appoints Ian Blackman as Chief Financial Officer https://ml.globenewswire.com/media/0e76fff8-7aee-4b60-ba26-62dda9975939/small/logo-png.png https://www.healthworldmauritania.com/article/908447609-adial-pharmaceuticals-submits-application-to-fda-commissioner-s-national-priority-voucher-cnpv-pilot-program-for-ad04-clinical-development-program Health World Mauritania en PressRelease 2026-04-27T12:47:00+00:00 Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program https://ml.globenewswire.com/media/e6fc09f7-5847-46c8-9294-f51162a7e518/small/adil-logo-png.png https://www.healthworldmauritania.com/article/908443556-terrascend-announces-preliminary-first-quarter-2026-financial-results-and-schedules-earnings-conference-call Health World Mauritania en PressRelease 2026-04-27T12:35:48+00:00 TerrAscend Announces Preliminary First Quarter 2026 Financial Results and Schedules Earnings Conference Call https://ml.globenewswire.com/media/3057ae6c-0bfe-49e0-90d4-66688bd859c8/small/picture1-png.png https://www.healthworldmauritania.com/article/908443320-akari-therapeutics-secures-australian-patent-approval-further-expanding-global-protection-of-its-proprietary-ph1-rna-splicing-modulator-adc-payload Health World Mauritania en PressRelease 2026-04-27T12:35:00+00:00 Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload https://ml.globenewswire.com/media/8d978f50-07a9-40a3-be69-45f51ccd94d9/small/akari-logo-1-jpg.jpg https://www.healthworldmauritania.com/article/908443298-cytodyn-announces-first-patient-dosed-in-expanded-access-program-for-leronlimab-in-triple-negative-breast-cancer Health World Mauritania en PressRelease 2026-04-27T12:30:00+00:00 CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png https://www.healthworldmauritania.com/article/908443314-iradimed-corporation-to-hold-first-quarter-2026-financial-results-conference-call-on-may-1-2026 Health World Mauritania en PressRelease 2026-04-27T12:30:00+00:00 IRADIMED CORPORATION to Hold First Quarter 2026 Financial Results Conference Call on May 1, 2026 https://ml.globenewswire.com/media/f353c867-559d-43a8-935c-ab497045e743/small/logo-gif.gif https://www.healthworldmauritania.com/article/908443366-tomi-environmental-solutions-inc-sees-strong-interest-in-its-solutions-at-interphex-2026 Health World Mauritania en PressRelease 2026-04-27T12:30:00+00:00 TOMI Environmental Solutions, Inc. Sees Strong Interest In Its Solutions at INTERPHEX 2026  https://ml.globenewswire.com/media/f8c7c513-0121-4507-84b7-3680626d9cf3/small/tomi-jpg.jpg https://www.healthworldmauritania.com/article/908443367-tenaya-therapeutics-announces-late-breaking-oral-presentation-of-new-clinical-data-from-ridge-1-phase-1b-2-clinical-trial-of-tn-401-gene-therapy-in Health World Mauritania en PressRelease 2026-04-27T12:30:00+00:00 Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 https://ml.globenewswire.com/media/95a7de9f-2b24-4ff3-9b57-f8a35e8c049f/small/tenaya-logo-fullcolor-rgb-jpg.jpg https://www.healthworldmauritania.com/article/908443425-erasca-to-host-conference-call-and-webcast-to-discuss-preliminary-phase-1-dose-escalation-data-for-potentially-best-in-class-pan-ras-molecular-glue Health World Mauritania en PressRelease 2026-04-27T12:30:00+00:00 Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 https://ml.globenewswire.com/media/266fe248-70d0-4904-b12e-e0d5a990f816/small/erascatm-logo-png.png https://www.healthworldmauritania.com/article/908443431-solana-company-nasdaq-hsdt-announces-registered-direct-offering-of-common-stock-to-global-institutional-investor Health World Mauritania en PressRelease 2026-04-27T12:30:00+00:00 Solana Company (NASDAQ: HSDT) Announces Registered Direct Offering of Common Stock to Global Institutional Investor https://ml.globenewswire.com/media/1986b97e-8656-4213-9218-ae51324d696d/small/solana-company-main-black-png.png https://www.healthworldmauritania.com/article/908443499-medipharm-labs-positioned-to-serve-growing-u-s-pharmaceutical-and-clinical-research-demand-following-cannabis-rescheduling Health World Mauritania en PressRelease 2026-04-27T12:30:00+00:00 MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling https://ml.globenewswire.com/media/7a534238-60aa-4187-979d-8f4d83fa58c1/small/medipharm-logo-jpg.jpg https://www.healthworldmauritania.com/article/908439011-oncolytics-aligns-with-fda-on-planned-pivotal-anal-cancer-study Health World Mauritania en PressRelease 2026-04-27T12:10:00+00:00 Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study https://ml.globenewswire.com/media/f0121259-b2be-4290-90a3-0d2c3b243aed/small/oncolytics-biotech-jpg.jpg https://www.healthworldmauritania.com/article/908438890-new-data-presented-at-hrs-2026-show-short-term-holter-monitoring-misses-a-large-proportion-of-af-recurrence-post-ablation-and-clinically-significant Health World Mauritania en PressRelease 2026-04-27T12:05:00+00:00 New Data Presented at HRS 2026 Show Short-Term Holter Monitoring Misses a Large Proportion of AF Recurrence Post-Ablation and Clinically Significant Arrhythmias in Pregnancy https://ml.globenewswire.com/media/e2eba87d-aa8b-4436-9f66-9ebf27f727e5/small/irhythm-rgb-indigo-jpg.jpg https://www.healthworldmauritania.com/article/908439006-terns-pharmaceuticals-announces-fda-breakthrough-therapy-designation-granted-to-tern-701-for-certain-patients-with-chronic-myeloid-leukemia Health World Mauritania en PressRelease 2026-04-27T12:05:00+00:00 Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia https://ml.globenewswire.com/media/cfd0bb0d-8a9b-4de4-92ce-47e8018cf3d9/small/terns-logo-rgbs-jpg.jpg https://www.healthworldmauritania.com/article/908438868-iovance-biotherapeutics-to-report-first-quarter-2026-financial-results-and-corporate-updates-on-thursday-may-7-2026 Health World Mauritania en PressRelease 2026-04-27T12:01:00+00:00 Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 https://ml.globenewswire.com/media/d0986bd6-4603-4e31-8ed1-f23b3e123605/small/iovance-jpg.jpg https://www.healthworldmauritania.com/article/908439043-ardelyx-announces-abstract-accepted-for-poster-presentation-at-the-nkf-s-spring-clinical-meetings Health World Mauritania en PressRelease 2026-04-27T12:01:00+00:00 Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings https://ml.globenewswire.com/media/cee4ae6d-7a85-44bf-9c02-87e7fa934ec2/small/ardelyx-logo-rgb-jpg.jpg https://www.healthworldmauritania.com/article/908438796-allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office https://ml-eu.globenewswire.com/media/fd1e4c64-f0cf-40e0-a0c9-0be0d6dce544/small/allarity-full-color-rgb-2023jun07-png.png https://www.healthworldmauritania.com/article/908438833-evaxion-promotes-birgitte-r-n-to-joint-role-of-chief-scientific-and-chief-operating-officer Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer https://ml-eu.globenewswire.com/media/19d0d69c-7f37-4d3b-8f26-2866d4ec3311/small/evaxion-deepblue-rgb-png.png https://www.healthworldmauritania.com/article/908438847-opus-genetics-to-participate-in-leading-medical-conferences-in-may-2026 Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Opus Genetics to Participate in Leading Medical Conferences in May 2026 https://ml.globenewswire.com/media/468baef1-3b2d-4353-a17e-cb41b45ee6ef/small/opus-rgb-r-jpg.jpg https://www.healthworldmauritania.com/article/908438864-biovie-to-host-virtual-kol-event-to-discuss-the-phase-2-study-of-bezisterim-for-the-treatment-of-parkinson-s-disease-ahead-of-topline-data-in-2q26-on Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026 https://ml.globenewswire.com/media/f437d04b-c089-46eb-bca8-7ef64f68bc9b/small/biovie-logo-jpg.jpg https://www.healthworldmauritania.com/article/908438904-real-world-data-on-exparel-shows-reduced-opioid-use-and-lower-total-medical-costs-in-medicare-patients-undergoing-total-hip-arthroplasty Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty https://ml.globenewswire.com/media/3e502c92-e576-46b6-b602-a177ab0f5044/small/pacira-biosciences-tm-logo-rgb-v2025-300dpi-adj-png.png https://www.healthworldmauritania.com/article/908438911-lifemd-to-report-first-quarter-2026-financial-results-on-may-6 Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 LifeMD to Report First Quarter 2026 Financial Results on May 6 https://ml.globenewswire.com/media/07c92c99-5645-4be8-a3b7-6d9392b7ccc4/small/lifemd-png.png https://www.healthworldmauritania.com/article/908438995-humacyte-to-host-virtual-kol-event-to-discuss-atev-for-arteriovenous-av-access-for-hemodialysis-patients-on-april-28-2026 Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 https://ml.globenewswire.com/media/e81aff26-ead8-404d-aebb-159b45c3e7b1/small/huma-logo-png.png https://www.healthworldmauritania.com/article/908439016-avalyn-strengthens-leadership-team-to-support-long-term-growth-with-appointments-of-industry-leaders-adam-golden-and-frank-salisbury Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury https://ml.globenewswire.com/media/84d7bff4-ce17-433b-8c71-aa20c30f9f43/small/avalyn-logo-final-png.png https://www.healthworldmauritania.com/article/908439020-replimune-to-present-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting https://ml.globenewswire.com/media/NzU1N2M2NzEtNmRkNS00ODQ0LTg0YmQtZTVjMDZhZTRlNjQ1LTExMjIxMDEtMjAyNi0wNC0yNy1lbg==/tiny/Replimune-Inc-.png https://www.healthworldmauritania.com/article/908439030-pharmala-executes-binding-letter-of-intent-for-formation-of-special-purpose-vehicle-to-develop-patented-novel-mdxx-molecule-apa-01 Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01 https://ml.globenewswire.com/media/20158980-8674-43e3-a0be-a10dca42410d/small/pharmala-biotech-logo-800-x-422-png.png https://www.healthworldmauritania.com/article/908439052-sol-sence-inc-announces-appointment-of-new-independent-director Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Solésence, Inc. Announces Appointment of New Independent Director https://ml.globenewswire.com/media/cd3e5e4e-9567-4a86-8f44-900ffeb29d33/small/solesence-fullcolor-300dpi-social-002-1-png.png https://www.healthworldmauritania.com/article/908439098-apollomics-reports-full-year-2025-financial-results-and-provides-clinical-updates-and-business-progress Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress https://ml.globenewswire.com/media/5d278096-e1c2-4350-b583-bca455f23b4b/small/apollomics-color-logo-1147x445-jpg.jpg https://www.healthworldmauritania.com/article/908439135-arcutis-submits-supplemental-new-drug-application-to-the-fda-for-zoryve-roflumilast-cream-0-05-to-expand-indication-for-treatment-of-atopic Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months https://ml.globenewswire.com/media/1b166f47-afb1-44f1-91be-2d73e97c0ec3/small/arcutis-logo-png.png https://www.healthworldmauritania.com/article/908439160-belite-bio-announces-oral-presentation-at-the-retinal-therapeutics-innovation-summit Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit https://ml.globenewswire.com/media/7f86ac70-6347-41c6-a622-e7000c42ad35/small/belite-bio-logo-digital-full-color-png.png https://www.healthworldmauritania.com/article/908439174-sbc-medical-announces-full-scale-rollout-of-aesthetic-healthcare-focused-interpretation-app-talk-bridge-across-all-shonan-beauty-clinic-locations Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 SBC Medical Announces Full-Scale Rollout of Aesthetic Healthcare-Focused Interpretation App "Talk Bridge" Across All Shonan Beauty Clinic Locations https://ml.globenewswire.com/media/5f64079d-47d0-4e3a-82ac-fe43557060de/medium/png.png https://www.healthworldmauritania.com/article/908439178-vystar-plans-dividend-spin-off-of-rxair-and-related-brands-following-r3alm-inc-transaction Health World Mauritania en PressRelease 2026-04-27T12:00:00+00:00 Vystar Plans Dividend Spin Off of RXAIR and Related Brands Following R3alm, Inc. Transaction https://ml.globenewswire.com/media/08188699-078a-4d6e-ae46-c56120bb0435/small/logo-jpg.jpg https://www.healthworldmauritania.com/article/908434497-clearmind-medicine-announces-evaluation-of-its-psychedelic-based-treatment-meai-for-potential-fda-breakthrough-therapy-designation Health World Mauritania en PressRelease 2026-04-27T11:41:00+00:00 Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://www.healthworldmauritania.com/article/908434367-briacell-announces-six-clinical-data-presentations-at-asco-2026 Health World Mauritania en PressRelease 2026-04-27T11:30:00+00:00 BriaCell Announces Six Clinical Data Presentations at ASCO 2026 https://ml.globenewswire.com/media/88b9408d-31d4-4afd-beff-f855719a15d8/small/briacell-logo-square-a-jpg.jpg https://www.healthworldmauritania.com/article/908434376-tovecimig-demonstrates-statistically-significant-benefit-in-companion-002-randomized-phase-2-3-study-in-patients-with-biliary-tract-cancer Health World Mauritania en PressRelease 2026-04-27T11:30:00+00:00 Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer https://ml.globenewswire.com/media/b8470129-5d30-4368-8074-d77404b65be8/small/compass-logo-rgb-outlines-png.png https://www.healthworldmauritania.com/article/908434378-nima-s-next-gen-portable-gluten-sensor-wins-gold-stevie-award-for-achievement-in-product-innovation Health World Mauritania en PressRelease 2026-04-27T11:30:00+00:00 NIMA’s Next-Gen Portable Gluten Sensor Wins Gold Stevie® Award for Achievement in Product Innovation https://ml.globenewswire.com/media/a025c49c-a270-4041-92e3-76d50d9bc27f/medium/nima-is-the-2026-gold-stevie-award-winner.png https://www.healthworldmauritania.com/article/908434384-medicus-pharma-ceo-meets-with-lawmakers-on-energy-commerce-committee-on-capitol-hill Health World Mauritania en PressRelease 2026-04-27T11:30:00+00:00 Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill https://ml.globenewswire.com/media/0f5af1d1-dfba-4810-baac-d1922c0558c1/small/medicus-logo-rgb-05-aspect-1500px-globe-newswire-2-jpg.jpg https://www.healthworldmauritania.com/article/908434390-weight-watchers-announces-actions-to-utilize-up-to-40-million-to-pay-down-debt Health World Mauritania en PressRelease 2026-04-27T11:30:00+00:00 Weight Watchers Announces Actions to Utilize Up to $40 million to Pay Down Debt https://ml.globenewswire.com/media/f435b439-7f75-4d2f-a6cc-0e4e2ed811ea/small/weightwatchers-wordmark-boldblue-png.png https://www.healthworldmauritania.com/article/908434404-hcw-biologics-delivers-a-major-update-for-its-t-cell-engager-program-revealing-mechanism-of-action-and-validating-tissue-factor-as-target-for Health World Mauritania en PressRelease 2026-04-27T11:30:00+00:00 HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors https://ml.globenewswire.com/media/5689edc3-6997-43a0-a20c-b34dc5f99b0f/small/hcw-logo-full-color-600x-jpeg-2-jpg.jpg https://www.healthworldmauritania.com/article/908434422-nervgen-pharma-strengthens-leadership-team-with-appointment-of-keith-vendola-as-chief-financial-officer Health World Mauritania en PressRelease 2026-04-27T11:30:00+00:00 NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png https://www.healthworldmauritania.com/article/908434429-cormedix-therapeutics-announces-positive-topline-results-from-phase-iii-respect-trial-assessing-rezzayo-for-the-prophylaxis-of-invasive-fungal Health World Mauritania en PressRelease 2026-04-27T11:30:00+00:00 CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients https://ml.globenewswire.com/media/a14d732c-3f66-4a3c-96bb-7fc8ba5797bb/small/crmd-logo-jpg.jpg https://www.healthworldmauritania.com/article/908434491-alterity-therapeutics-receives-positive-fda-feedback-following-second-type-c-meeting-on-ath434-phase-3-program-in-multiple-system-atrophy Health World Mauritania en PressRelease 2026-04-27T11:25:00+00:00 Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy https://ml.globenewswire.com/media/0771a9a2-2ac1-4a63-9767-a2b1df74af27/small/alterity-png.png https://www.healthworldmauritania.com/article/908430295-suja-life-announces-launch-of-initial-public-offering Health World Mauritania en PressRelease 2026-04-27T11:20:40+00:00 Suja Life Announces Launch of Initial Public Offering https://ml.globenewswire.com/media/9022887d-dd69-416f-9a4b-ce5e546d75e4/small/suja-life-horizontal-black-1-png.png https://www.healthworldmauritania.com/article/908430292-sagimet-biosciences-announces-pricing-of-175-0-million-underwritten-offering-of-series-a-common-stock Health World Mauritania en PressRelease 2026-04-27T11:15:04+00:00 Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock https://ml.globenewswire.com/media/e944daed-3f71-402b-bb23-82149e5c0d26/small/sagimet-logo-for-light-bg-fin-png.png https://www.healthworldmauritania.com/article/908429883-fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-first-quarter-2026 Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 https://ml.globenewswire.com/media/3434fc83-4bcf-4d3c-ae26-23e5b1fd4252/small/fulcrum-logo-primary-full-color-rgb-large-png.png https://www.healthworldmauritania.com/article/908429920-sionna-therapeutics-completes-enrollment-in-precision-cf-phase-2a-trial-evaluating-nbd1-stabilizer-sion-719-added-to-standard-of-care-in Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis https://ml.globenewswire.com/media/0cda8c25-e758-4f0d-86f2-875df8411a9a/small/sionna-png.png https://www.healthworldmauritania.com/article/908430027-secura-bio-announces-journal-of-clinical-oncology-publication-of-final-results-of-duvelisib-primo-phase-2-trial-in-relapsed-refractory-peripheral Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma https://ml.globenewswire.com/media/0c6ab6dc-8076-44dc-acba-60a586a93721/small/securabio-brand-rgb-logo-fullcolor-png.png https://www.healthworldmauritania.com/article/908430111-oruka-therapeutics-announces-positive-week-16-data-for-orka-001-from-the-ongoing-everlast-a-phase-2a-trial-in-moderate-to-severe-plaque-psoriasis Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis https://ml.globenewswire.com/media/3950d2d7-850d-459a-9e42-07c642a841c5/small/oruka-full-color-jpg.jpg https://www.healthworldmauritania.com/article/908430156-intellia-therapeutics-reports-positive-phase-3-results-in-hereditary-angioedema-marking-a-global-first-for-in-vivo-gene-editing Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://www.healthworldmauritania.com/article/908430163-intellia-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-lonvoguran-ziclumeran-lonvo-z-as-a-one-time-treatment Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://www.healthworldmauritania.com/article/908430186-harrow-to-report-first-quarter-2026-financial-results-after-market-close-on-may-11-2026 Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026 https://ml.globenewswire.com/media/8e0382bf-e00a-4591-87aa-4e90001aabea/small/bw-harrow-logo-cmyk-wtag-wr-jpg.jpg https://www.healthworldmauritania.com/article/908430187-altimmune-announces-closing-of-225-million-oversubscribed-public-offering-of-securities Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities https://ml.globenewswire.com/media/362fbdfa-dc07-456c-9908-9e042540158a/small/altimmune-logo-png.png https://www.healthworldmauritania.com/article/908430189-cardiff-oncology-to-host-key-opinion-leader-discussion-on-onvansertib-s-promising-single-agent-activity Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity https://ml.globenewswire.com/media/916adb81-8173-4fbe-8095-c284c4f44cd3/small/cardiff-jpg.jpg https://www.healthworldmauritania.com/article/908430195-sagimet-biosciences-provides-strategic-and-corporate-updates Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Sagimet Biosciences Provides Strategic and Corporate Updates https://ml.globenewswire.com/media/e944daed-3f71-402b-bb23-82149e5c0d26/small/sagimet-logo-for-light-bg-fin-png.png https://www.healthworldmauritania.com/article/908430198-ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.healthworldmauritania.com/article/908430200-seer-board-of-directors-unanimously-rejects-revised-unsolicited-proposal-from-radoff-jec-group Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group https://ml.globenewswire.com/media/a5aaadad-13a1-4dbd-8ba2-d57cbbc610fb/small/seer-brandmark-rgb-full-jpg.jpg https://www.healthworldmauritania.com/article/908430206-ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-s-position-as-a-leading-biopharma-royalty-aggregator Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator https://ml.globenewswire.com/media/46cbb269-1ae4-4441-a46a-d782ffb436dc/small/xoma-royalty-2c-png.png https://www.healthworldmauritania.com/article/908430207-ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-s-position-as-a-leading-biopharma-royalty-aggregator Health World Mauritania en PressRelease 2026-04-27T11:00:00+00:00 Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator  https://ml.globenewswire.com/media/1fe91aa2-494e-4b30-89e8-cad771bbaabf/small/new-ligand-logo-png.png https://www.healthworldmauritania.com/article/908425638-fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors Health World Mauritania en PressRelease 2026-04-27T10:55:00+00:00 Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors https://ml.globenewswire.com/media/3434fc83-4bcf-4d3c-ae26-23e5b1fd4252/small/fulcrum-logo-primary-full-color-rgb-large-png.png https://www.healthworldmauritania.com/article/908425640-eton-pharmaceuticals-announces-initiation-of-clinical-study-for-product-candidate-et-700 Health World Mauritania en PressRelease 2026-04-27T10:50:00+00:00 Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 https://ml.globenewswire.com/media/db07cafa-b35c-4d61-a1a1-d330caf67ad2/small/eton-logo-png.png https://www.healthworldmauritania.com/article/908421856-conference-to-focus-on-how-artificial-intelligence-can-dramatically-reduce-workplace-injuries Health World Mauritania en PressRelease 2026-04-27T10:30:00+00:00 Conference to focus on how artificial intelligence can dramatically reduce workplace injuries https://ml.globenewswire.com/media/NWJjMjI4MmQtZDhhYy00MTg2LWI0OTYtYmM4N2Y3ZWViNGI5LTUwMDE2MTY5NC0yMDI2LTA0LTI3LWVu/tiny/4S-Consulting-Inc-.png https://www.healthworldmauritania.com/article/908418144-relay-therapeutics-announces-clinical-data-for-zovegalisib-plus-atirmociclib-triplet-combination-supportive-of-further-development-in-frontline Health World Mauritania en PressRelease 2026-04-27T10:00:00+00:00 Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer https://ml.globenewswire.com/media/079b6db5-ce81-4a81-9cde-d97f86c569ae/small/logo-banner-small-png.png https://www.healthworldmauritania.com/article/908418159-kfsh-highlights-scalable-ai-integration-model-at-c3-davos-of-healthcare-silicon-valley-summit Health World Mauritania en PressRelease 2026-04-27T09:51:07+00:00 KFSH Highlights Scalable AI Integration Model at C3 Davos of Healthcare™ Silicon Valley Summit https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.healthworldmauritania.com/article/908401914-ataibeckley-and-psypan-receive-a-silver-award-in-2026-patient-participant-index-reflecting-ongoing-commitment-to-participant-informed-research Health World Mauritania en PressRelease 2026-04-27T08:05:00+00:00 AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research https://ml.globenewswire.com/media/cea08bf4-0562-45ed-af5c-c9376c48a6eb/small/ataibeckley-horizontal-2color-png.png https://www.healthworldmauritania.com/article/908392273-fangzhou-publishes-2025-annual-report-advancing-ai-powered-chronic-care-strategy-for-2026 Health World Mauritania en PressRelease 2026-04-27T06:52:35+00:00 Fangzhou Publishes 2025 Annual Report, Advancing AI-Powered Chronic Care Strategy for 2026 https://ml.globenewswire.com/media/294c081f-a526-49c8-925a-1e407972f343/small/logo-compressed-png.png https://www.healthworldmauritania.com/article/908381127-ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101-for-prevention-of-organ-rejection-in-heart-transplant Health World Mauritania en PressRelease 2026-04-27T05:30:00+00:00 OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://www.healthworldmauritania.com/article/908381134-ose-immunotherapeutics-se-f-licite-de-l-octroi-de-la-d-signation-de-m-dicament-orphelin-par-la-fda-du-pegrizeprument-vel-101-pour-la-pr-vention-du Health World Mauritania en PressRelease 2026-04-27T05:30:00+00:00 OSE Immunotherapeutics se félicite de l'octroi de la désignation de médicament orphelin par la FDA du pegrizeprument (VEL-101) pour la prévention du rejet d’organe dans la transplantation cardiaque https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://www.healthworldmauritania.com/article/908378484-santhera-erh-lt-positive-stellungnahme-des-chmp-zur-ausweitung-der-anwendung-von-agamree-vamorolon-bei-p-diatrischen-dmd-patienten-ab-zwei-jahren Health World Mauritania en PressRelease 2026-04-27T05:00:00+00:00 Santhera erhält positive Stellungnahme des CHMP zur Ausweitung der Anwendung von AGAMREE® (Vamorolon) bei pädiatrischen DMD-Patienten ab zwei Jahren in der EU https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/ https://www.healthworldmauritania.com/article/908378495-santhera-receives-positive-chmp-opinion-to-expand-agamree-vamorolone-use-in-pediatric-dmd-patients-aged-two-and-older-in-the-eu Health World Mauritania en PressRelease 2026-04-27T05:00:00+00:00 Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/logo-jpg.JPG https://www.healthworldmauritania.com/article/908367164-dark-horse-consulting-group-and-porton-advanced-announce-memorandum-of-understanding-providing-a-streamlined-path-to-conducting-iits-in-china Health World Mauritania en PressRelease 2026-04-27T03:30:00+00:00 Dark Horse Consulting Group and Porton Advanced Announce Memorandum of Understanding Providing a Streamlined Path to Conducting IITs in China https://ml.globenewswire.com/media/b96e7c60-949b-4a7d-9d4e-8d9766cf8c87/small/2025-dhcg-logo-color-jpg.jpg https://www.healthworldmauritania.com/article/908282227-oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-a-trial-on-april-27-2026 Health World Mauritania en PressRelease 2026-04-26T16:00:00+00:00 Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026 https://ml.globenewswire.com/media/3950d2d7-850d-459a-9e42-07c642a841c5/small/oruka-full-color-jpg.jpg https://www.healthworldmauritania.com/article/908279678-c3-davos-of-healthcare-silicon-valley-summit-opens-tomorrow-in-sunnyvale-with-kfsh Health World Mauritania en PressRelease 2026-04-26T15:50:00+00:00 C3 Davos of Healthcare™ Silicon Valley Summit Opens Tomorrow in Sunnyvale with KFSH https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.healthworldmauritania.com/article/908279684-c3-davos-of-healthcare-silicon-valley-summit-tem-in-cio-amanh-em-sunnyvale-com-a-presen-a-do-kfsh Health World Mauritania en PressRelease 2026-04-26T15:50:00+00:00 C3 Davos of Healthcare™ Silicon Valley Summit Tem Início Amanhã em Sunnyvale com a Presença do KFSH https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.healthworldmauritania.com/article/908279687-el-c3-davos-of-healthcare-silicon-valley-summit-se-inaugura-ma-ana-en-sunnyvale-con-kfsh Health World Mauritania en PressRelease 2026-04-26T15:50:00+00:00 El C3 Davos of Healthcare™ Silicon Valley Summit se inaugura mañana en Sunnyvale con KFSH https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.healthworldmauritania.com/article/908179975-heroup-claims-evaluated-investigating-the-supplement-facts-about-hero-up-capsules-for-hardero-male-enhancement-support Health World Mauritania en PressRelease 2026-04-26T01:13:17+00:00 HeroUp Claims Evaluated: Investigating the Supplement Facts About Hero Up Capsules for Hardero Male Enhancement Support https://zingfast.com/wp-content/uploads/2026/04/HeroUp-Male-Enhancement.jpg https://www.healthworldmauritania.com/article/908160348-quad-ed-under-investigation-safe-clinician-prescribed-ed-medication-using-sildenafil-tadalafil-vardenafil-and-apomorphine-for-men Health World Mauritania en PressRelease 2026-04-25T22:24:56+00:00 Quad ED Under Investigation: Safe Clinician-Prescribed ED Medication Using Sildenafil, Tadalafil, Vardenafil and Apomorphine for Men https://zingfast.com/wp-content/uploads/2026/04/Quad-ED.jpg https://www.healthworldmauritania.com/article/908132022-healthrx-blood-support-claims-evaluated-the-health-rx-blood-pressure-optimizer-formula-under-investigation Health World Mauritania en PressRelease 2026-04-25T19:10:06+00:00 HealthRX Blood Support Claims Evaluated: The Health RX Blood Pressure Optimizer Formula Under Investigation https://zingfast.com/wp-content/uploads/2026/04/Health-RX-Blood-Pressure-Optimizer-Formula.jpg https://www.healthworldmauritania.com/article/908097107-study-shows-implicity-s-new-agnostic-cloud-based-ai-algorithm-further-reduces-false-alerts-even-after-manufacturer-ai-filtering-in-modern-devices Health World Mauritania en PressRelease 2026-04-25T15:00:00+00:00 Study Shows Implicity’s New Agnostic Cloud-Based AI Algorithm Further Reduces False Alerts Even After Manufacturer AI Filtering in Modern Devices https://ml.globenewswire.com/media/d7822800-7d4d-420d-aa7f-89a50a370756/small/implicity-logo-jpg.jpg https://www.healthworldmauritania.com/article/908094243-kfsh-advances-precision-surgery-through-in-house-3d-printing-program Health World Mauritania en PressRelease 2026-04-25T14:45:00+00:00 KFSH Advances Precision Surgery Through In-House 3D Printing Program https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.healthworldmauritania.com/article/908094260-kfsh-avanza-en-la-cirug-a-de-precisi-n-mediante-un-programa-interno-de-impresi-n-3d Health World Mauritania en PressRelease 2026-04-25T14:45:00+00:00 KFSH avanza en la cirugía de precisión mediante un programa interno de impresión 3D https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.healthworldmauritania.com/article/908094264-kfsh-avan-a-na-cirurgia-de-precis-o-com-o-programa-interno-de-impress-o-3d Health World Mauritania en PressRelease 2026-04-25T14:45:00+00:00 KFSH Avança na Cirurgia de Precisão Com o Programa Interno de Impressão 3D https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png